GU Cancer

PARP inhibitors should be first line treatment in all women with ovarian cancer

The results of three eagerly anticipated trials on the use of PARP inhibitors in ovarian cancer signal a big step forward in the treatment of women with advanced ovarian cancer, regardless of their BRCA status.  Late-breaking results of the phase III PAOLA-1/ENGOT-ov25 trial revealed that treatment with the PARP inhibitor olaparib in combination with bevacizumab ...

Already a member?

Login to keep reading.

© 2021 the limbic